iSAM Funds UK Ltd Buys Shares of 2,295 McKesson Corporation $MCK

iSAM Funds UK Ltd bought a new stake in McKesson Corporation (NYSE:MCK) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,295 shares of the company’s stock, valued at approximately $1,773,000.

Several other large investors have also recently made changes to their positions in the company. Obsidian Personal Planning Solutions LLC boosted its stake in McKesson by 2.9% during the 3rd quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock worth $346,000 after purchasing an additional 12 shares during the last quarter. IAM Advisory LLC grew its holdings in shares of McKesson by 0.3% during the third quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock worth $3,019,000 after buying an additional 13 shares in the last quarter. PDS Planning Inc raised its position in shares of McKesson by 1.1% in the third quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock valued at $934,000 after buying an additional 13 shares during the last quarter. Berkshire Asset Management LLC PA raised its position in shares of McKesson by 4.6% in the third quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock valued at $227,000 after buying an additional 13 shares during the last quarter. Finally, Goldstein Advisors LLC lifted its stake in shares of McKesson by 4.4% in the third quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock worth $258,000 after buying an additional 14 shares in the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

McKesson Trading Down 0.3%

Shares of MCK opened at $941.51 on Friday. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00. The firm has a market capitalization of $115.33 billion, a P/E ratio of 27.08, a P/E/G ratio of 1.52 and a beta of 0.38. The firm has a 50-day moving average price of $893.90 and a 200 day moving average price of $824.34.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The company had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. McKesson’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Equities research analysts predict that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s payout ratio is presently 9.43%.

Analyst Ratings Changes

A number of research firms recently weighed in on MCK. Weiss Ratings lowered shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. JPMorgan Chase & Co. raised their target price on shares of McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Morgan Stanley restated an “overweight” rating and set a $966.00 target price on shares of McKesson in a report on Thursday, January 29th. Robert W. Baird set a $968.00 price target on McKesson in a research report on Wednesday, January 14th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of McKesson in a report on Wednesday, December 10th. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $960.93.

Insider Transactions at McKesson

In related news, EVP Michele Lau sold 2,725 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total value of $2,697,750.00. Following the transaction, the executive vice president directly owned 3,247 shares in the company, valued at approximately $3,214,530. This represents a 45.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Thomas L. Rodgers sold 276 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the transaction, the executive vice president owned 2,268 shares of the company’s stock, valued at $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,868 shares of company stock valued at $3,743,820 in the last ninety days. 0.08% of the stock is currently owned by corporate insiders.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.